(Q80204033)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

[New approaches in obesity treatment: the gastrointestinal tract as an endocrine organ] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Manuela Belén Silveira Rodríguez

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Antonio Gómez-Pan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Raffaele Carraro Casieri

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 September 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

300-305

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

The mechanism of pancreatic secretion

29 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Cholecystokinin decreases food intake in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

The gut and energy balance: visceral allies in the obesity wars

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Orexins in the brain-gut axis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Orexin synthesis and response in the gut.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Ghrelin: more than a natural GH secretagogue and/or an orexigenic factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Ghrelin induces adiposity in rodents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Ghrelin causes hyperphagia and obesity in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Low Plasma Ghrelin Is Associated With Insulin Resistance, Hypertension, and the Prevalence of Type 2 Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Ghrelin and the metabolic syndrome in older adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Novel analogs of ghrelin: physiological and clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Antagonism of ghrelin receptor reduces food intake and body weight gain in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

7 January 2021

Ingested fat and satiety

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Oxyntomodulin suppresses appetite and reduces food intake in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Current and investigational antiobesity agents and obesity therapeutic treatment targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Gut hormone PYY(3-36) physiologically inhibits food intake

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

PYY3-36 as an anti-obesity drug target.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Peptide YY3-36 and satiety: clarity or confusion?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

The therapeutic potential of gut hormone peptide YY3-36 in the treatment of obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Inhibition of food intake in obese subjects by peptide YY3-36

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Attenuated peptide YY release in obese subjects is associated with reduced satiety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Peptide YY: a potential therapy for obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino}nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7753%2806%2972238-2

10.1016/S0025-7753(06)72238-2

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16949016%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference